$TSHA
Taysha Gene Therapies, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024059555 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.112M $3.411M
YoY Change -53.67% -27.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.338M $7.084M
YoY Change 22.55% -19.05%
% of Gross Profit
Research & Development $15.07M $20.66M
YoY Change -23.84% 65.07%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K
YoY Change -25.0% 0.0%
% of Gross Profit
Operating Expenses $22.41M $27.74M
YoY Change -13.06% 30.45%
Operating Profit -$21.30M -$24.33M
YoY Change -8.92% 46.93%
Interest Expense $27.00K $29.00K
YoY Change -98.13% -97.89%
% of Operating Profit
Other Income/Expense, Net $371.0K $269.0K
YoY Change -130.56% -125.31%
Pretax Income -$20.93M -$24.06M
YoY Change -14.92% 36.54%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.93M -$24.06M
YoY Change -14.92% 36.54%
Net Earnings / Revenue -1882.01% -705.39%
Basic Earnings Per Share -$0.09 -$0.10
Diluted Earnings Per Share -$0.09 -$0.10
COMMON SHARES
Basic Shares Outstanding 187.0M 187.0M
Diluted Shares Outstanding 232.8M 231.2M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.7M $124.0M
YoY Change 283.17% 95.47%
Cash & Equivalents $172.7M $124.0M
Short-Term Investments
Other Short-Term Assets $206.0K $149.0K
YoY Change -59.61% -71.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $178.5M $130.6M
YoY Change 229.8% 80.49%
LONG-TERM ASSETS
Property, Plant & Equipment $10.51M $10.69M
YoY Change -25.65% -27.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $288.0K $304.0K
YoY Change -5.26% -76.9%
Total Long-Term Assets $21.92M $22.40M
YoY Change -20.07% -23.39%
TOTAL ASSETS
Total Short-Term Assets $178.5M $130.6M
Total Long-Term Assets $21.92M $22.40M
Total Assets $200.4M $153.0M
YoY Change 145.75% 50.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.718M $10.38M
YoY Change -19.02% 15.31%
Accrued Expenses $10.73M $12.42M
YoY Change -42.36% -25.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $371.0K $362.0K
YoY Change 10.09% 10.37%
Total Short-Term Liabilities $34.18M $38.64M
YoY Change -32.51% -29.05%
LONG-TERM LIABILITIES
Long-Term Debt $37.84M $40.51M
YoY Change -1.35% 6.16%
Other Long-Term Liabilities $1.380M $1.502M
YoY Change -64.81% -62.49%
Total Long-Term Liabilities $39.22M $42.01M
YoY Change -7.24% -0.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.18M $38.64M
Total Long-Term Liabilities $39.22M $42.01M
Total Liabilities $91.53M $99.15M
YoY Change -22.87% -14.93%
SHAREHOLDERS EQUITY
Retained Earnings -$558.0M -$537.1M
YoY Change 25.76% 28.16%
Common Stock $2.000K $2.000K
YoY Change 100.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.9M $53.85M
YoY Change
Total Liabilities & Shareholders Equity $200.4M $153.0M
YoY Change 145.75% 50.59%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$20.93M -$24.06M
YoY Change -14.92% 36.54%
Depreciation, Depletion And Amortization $300.0K $300.0K
YoY Change -25.0% 0.0%
Cash From Operating Activities -$21.50M -$19.80M
YoY Change 14.58% -1.92%
INVESTING ACTIVITIES
Capital Expenditures $201.0K $140.0K
YoY Change -518.75% -96.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$201.0K -$140.0K
YoY Change -518.75% -96.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.47M -22.00K
YoY Change 18591.78% -94.05%
NET CHANGE
Cash From Operating Activities -21.50M -19.80M
Cash From Investing Activities -201.0K -140.0K
Cash From Financing Activities 70.47M -22.00K
Net Change In Cash 48.76M -19.96M
YoY Change -365.85% -18.38%
FREE CASH FLOW
Cash From Operating Activities -$21.50M -$19.80M
Capital Expenditures $201.0K $140.0K
Free Cash Flow -$21.71M -$19.94M
YoY Change 15.95% -17.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001806310
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2024Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2024Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2024Q1 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#Liabilities
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39536
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Drive
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
CY2024Q1 dei City Area Code
CityAreaCode
214
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
612-0000
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
TSHA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
187018275
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123980000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143940000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
449000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
449000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4168000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3479000
CY2024Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2000000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2000000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
130597000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
149868000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2151000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2151000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10686000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10826000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9261000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9582000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000
CY2024Q1 us-gaap Assets
Assets
152999000
CY2023Q4 us-gaap Assets
Assets
172731000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
10380000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6366000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13562000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12284000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14695000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18106000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
38637000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36756000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40512000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40508000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
319000
CY2024Q1 us-gaap Interest Expense
InterestExpense
29000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1374000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123980000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63425000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
2600000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
126580000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
269000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18499000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18953000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1502000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1577000
CY2024Q1 us-gaap Liabilities
Liabilities
99150000
CY2023Q4 us-gaap Liabilities
Liabilities
97794000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187018275
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
187018275
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
186960193
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
186960193
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
591166000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587942000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-251000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-537068000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513007000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
53849000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
74937000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152999000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
172731000
CY2024Q1 us-gaap Revenues
Revenues
3411000
CY2023Q1 us-gaap Revenues
Revenues
4706000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20657000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12514000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7084000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8751000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
27741000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
21265000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24330000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16559000
CY2024Q1 tsha Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
337000
CY2024Q1 tsha Change In Fair Value Of Term Loan
ChangeInFairValueOfTermLoan
1053000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1693000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1063000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-24061000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231249344
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231249344
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63260905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63260905
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-24061000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2024Q1 tsha Gain Loss On Fair Value Of Terms Loan Attributable To Instrument Specific Credit Risk
GainLossOnFairValueOfTermsLoanAttributableToInstrumentSpecificCreditRisk
-251000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24312000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17622000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
74937000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3198000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
26000
CY2024Q1 tsha Stock Issued During Period Value Loss On Instrument Specific Credit Risk
StockIssuedDuringPeriodValueLossOnInstrumentSpecificCreditRisk
-251000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-24061000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
53849000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1675000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14948000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24061000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-17622000
CY2024Q1 us-gaap Depreciation
Depreciation
325000
CY2023Q1 us-gaap Depreciation
Depreciation
331000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3198000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1675000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
337000
CY2024Q1 tsha Non Cash Change In Fair Value Of Term Loan
NonCashChangeInFairValueOfTermLoan
-247000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
325000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
300000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-27000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-128000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
693000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
400000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3980000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
359000
CY2024Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
422000
CY2023Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-250000
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3411000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4706000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19798000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20185000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
140000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3900000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3900000
CY2024Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
18000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
387000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
26000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
50000
CY2024Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-30000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-22000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-370000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19960000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24455000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
146540000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
126580000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123980000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63425000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
2600000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
126580000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1329000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1125000
CY2024Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
52000
CY2023Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
112000
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1329000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1125000
CY2024Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
52000
CY2023Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
112000
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-537100000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124000000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering (“IPO”) (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">the valuation of the Trinity Term Loans that are carried at fair value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the allocation of consideration received in connection with the Astellas Transactions (as defined below). These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering (“IPO”) (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">the valuation of the Trinity Term Loans that are carried at fair value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the allocation of consideration received in connection with the Astellas Transactions (as defined below). These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
122916000
CY2024Q1 tsha Trinity Term Loans
TrinityTermLoans
40512000
CY2024Q1 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
826000
CY2024Q1 tsha Ssi Warrants
SsiWarrants
791000
CY2024Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
42129000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
142425000
CY2023Q4 tsha Trinity Term Loans
TrinityTermLoans
40508000
CY2023Q4 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
800000
CY2023Q4 tsha Ssi Warrants
SsiWarrants
454000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
41762000
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
122916000
CY2024Q1 tsha Trinity Term Loans
TrinityTermLoans
40512000
CY2024Q1 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
826000
CY2024Q1 tsha Ssi Warrants
SsiWarrants
791000
CY2024Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
42129000
CY2023Q4 tsha Trinity Term Loans
TrinityTermLoans
40508000
CY2023Q4 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
800000
CY2023Q4 tsha Ssi Warrants
SsiWarrants
454000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
41762000
CY2023Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1412000
CY2024Q1 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
955000
CY2023Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
802000
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
681000
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
681000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
269000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
292000
CY2024Q1 tsha Prepaid Bonus
PrepaidBonus
193000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
149000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
292000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4168000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3479000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3311000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2979000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10686000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10826000
CY2024Q1 us-gaap Depreciation
Depreciation
300000
CY2023Q1 us-gaap Depreciation
Depreciation
300000
CY2024Q1 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1921000
CY2023Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1412000
CY2024Q1 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
955000
CY2023Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
802000
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
681000
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
681000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
269000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
292000
CY2024Q1 tsha Prepaid Bonus
PrepaidBonus
193000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
149000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
292000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4168000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3479000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13997000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13805000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3311000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2979000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10686000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10826000
CY2024Q1 us-gaap Depreciation
Depreciation
300000
CY2023Q1 us-gaap Depreciation
Depreciation
300000
CY2024Q1 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6078000
CY2023Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3467000
CY2024Q1 tsha Lease Liability Current
LeaseLiabilityCurrent
1696000
CY2023Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1646000
CY2024Q1 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1598000
CY2023Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1851000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1576000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3423000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2024Q1 tsha Warrant Liability Current
WarrantLiabilityCurrent
791000
CY2023Q4 tsha Warrant Liability Current
WarrantLiabilityCurrent
454000
CY2024Q1 tsha Accrued Severance
AccruedSeverance
28000
CY2023Q4 tsha Accrued Severance
AccruedSeverance
390000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13562000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12284000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
646000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
198000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
243000
CY2024Q1 us-gaap Lease Cost
LeaseCost
844000
CY2023Q1 us-gaap Lease Cost
LeaseCost
951000
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M17D
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2024Q1 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6078000
CY2023Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3467000
CY2024Q1 tsha Lease Liability Current
LeaseLiabilityCurrent
1696000
CY2023Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1646000
CY2024Q1 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1598000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3423000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2024Q1 tsha Warrant Liability Current
WarrantLiabilityCurrent
791000
CY2023Q4 tsha Warrant Liability Current
WarrantLiabilityCurrent
454000
CY2024Q1 tsha Accrued Severance
AccruedSeverance
28000
CY2023Q4 tsha Accrued Severance
AccruedSeverance
390000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
781000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
723000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13562000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12284000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
646000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
198000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
243000
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M17D
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M17D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M17D
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0781
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2742000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2123000
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
341000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2910000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2485000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
399000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2577000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2673000
CY2024Q1 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
17045000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29813000
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1194000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9980000
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
156000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19833000
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1038000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1334000
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
362000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18499000
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
676000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19833000
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1038000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0781
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2742000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
692000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2123000
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
341000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2910000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2485000
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
399000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2577000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2673000
CY2024Q1 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
17045000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29813000
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1194000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9980000
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
156000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19833000
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1038000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1334000
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
362000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18499000
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
676000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
19833000
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1038000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14700000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18709000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
21291000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000
CY2023Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14700000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18709000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
21291000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000
CY2023Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
9348009
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
12099322
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
120227
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4531639
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7162725
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
9348009
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
12099322
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
120227
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4531639
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3198000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1675000
CY2024Q1 tsha Common Stock And Warrants Fair Value Disclosure
CommonStockAndWarrantsFairValueDisclosure
149953
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1675000
CY2024Q1 tsha Common Stock And Warrants Fair Value Disclosure
CommonStockAndWarrantsFairValueDisclosure
149953
CY2023Q4 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
454000
CY2024Q1 tsha Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
337000
CY2024Q1 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
791000
CY2023Q4 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
454000
CY2024Q1 tsha Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
337000
CY2024Q1 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
791000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24061000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17622000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231249344
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231249344
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63260905
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63260905
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20137101
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6179633
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24061000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17622000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231249344
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231249344
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63260905
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63260905
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20137101
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2024Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000

Files In Submission

Name View Source Status
0000950170-24-059555-index-headers.html Edgar Link pending
0000950170-24-059555-index.html Edgar Link pending
0000950170-24-059555.txt Edgar Link pending
0000950170-24-059555-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img39569174_0.jpg Edgar Link pending
img39569174_1.jpg Edgar Link pending
img39569174_2.jpg Edgar Link pending
img39569174_3.jpg Edgar Link pending
img39569174_4.jpg Edgar Link pending
img39569174_5.jpg Edgar Link pending
img39569174_6.jpg Edgar Link pending
img39569174_7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20240331.htm Edgar Link pending
tsha-20240331.xsd Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tsha-20240331_htm.xml Edgar Link completed